中国·永兴集团(yx5978)有限公司-官方网站

In October 2026, Endovastec™ participated in two leading international vascular surgery events, the European Society for Vascular Surgery Annual Meeting (ESVS 2026) and the Congress of the Asian Society for Vascular Surgery (ASVS 2026). Through product exhibitions, academic exchange, clinical experience sharing, and discussions on real-world data, Endovastec™ showcased its innovative achievements and total solutions in aortic intervention, further strengthening its global presence and influence within the international vascular community.

ESVS 2026: Expert Insights. Advanced Technology. Real-World Experience. Exploring the Frontiers of Complex Aortic Disease Management

The future of vascular care took centre stage in Belgrade, Serbia, as the 40th Annual Meeting of the European Society for Vascular Surgery (ESVS 2026) brought together around 2,000 vascular experts, researchers, and industry representatives from 6–9 October 2026. As one of the most influential academic events in the global vascular field, the meeting provided an important platform for scientific exchange, clinical discussion, and the presentation of innovative treatment approaches.

Endovastec™ was proud to be part of the conversation, engaging with vascular specialists and showcasing its comprehensive portfolio of TEVAR, EVAR, and FEVAR solutions. With a shared commitment to improving patient outcomes and expanding therapeutic possibilities, the team connected with clinicians to discuss the latest technologies and future directions in aortic disease management.

During the meeting, two highly attended symposiums brought internationally renowned physicians to the stage to share their clinical expertise and real-world experience with Endovastec™’s advanced technologies.

Discussions explored the role of the Cratos™ Thoracic Branch Stent Graft System in aortic arch repair and the Hector™ Multi-Branch Thoracic Stent Graft System, alongside the Talos™ Thoracic Stent Graft System. Experts shared valuable insights into complex aortic interventions, including strategies to mitigate risk, address neurological complications and manage Type B aortic dissection (TBAD).

ASVS 2026: Showcasing Advanced Solutions for Aortic Disease Management

The 27th Congress of the Asian Society for Vascular Surgery (ASVS 2026) was successfully held in New Delhi, India, from October 8–10, 2026. As one of the most influential vascular surgery congresses in the Asia-Pacific region, the event brought together more than 400 experts and scholars to exchange insights on the latest advances in vascular disease diagnosis, treatment technologies and clinical practice.

Endovastec™ showcased a range of innovative products and solutions at the congress, including the Castor™ Branched Aortic Stent Graft System, Talos™ Thoracic Stent Graft System, Minos™ Abdominal Aortic Stent Graft and Delivery System, and the Hector™ Multi-Branch Thoracic Stent Graft System. Together, these solutions highlighted Endovastec™’s technological capabilities and commitment to addressing diverse clinical needs in aortic disease treatment.

The exhibition booth attracted considerable interest from vascular specialists and experts from multiple countries and regions. Through in-depth academic discussions and professional exchanges, Endovastec™ engaged with international experts on evolving clinical needs, technological innovation and interventional strategies for aortic disease management, further promoting international academic exchange and collaboration.

Over the years, Endovastec™ has maintained an active presence across the global vascular surgery community, regularly participating in major international academic conferences and professional platforms, including ESVS, ASVS, Charing Cross (CX), and VEITH. Through dedicated symposiums, clinical research exchanges, product exhibitions, and collaborations with renowned experts, Endovastec™ continuously fosters deeper engagement and broader collaboration across the global vascular surgery community.

As one of the leading innovators in aortic and peripheral vascular intervention industry, Endovastec™ remains committed to addressing unmet clinical needs through continuous technological innovation and product development. The company has established a comprehensive portfolio covering aortic, peripheral vascular, and tumor intervention solutions, while steadily expanding its global footprint.

With ongoing progress in international product registrations, clinical collaborations, and market development, Endovastec™’s products are being adopted in an increasing number of countries and regions, providing physicians and patients worldwide with more treatment options.

Looking ahead, Endovastec™ will continue advancing its globalization strategy, deepening international academic collaboration and industry partnerships, accelerating the global adoption of its innovative technologies, and remaining dedicated to advancing vascular disease treatment worldwide.

This article does not constitute any form of medical advice or product promotion. For any medical diagnostic issues, please be sure to consult qualified healthcare professionals.